Blackstone Mulls Bid for Glaxo Portfolio

Blackstone is working with Prestige Brands of America to bid on a portfolio of over-the-counter drugs owned by GlaxoSmithKline, Reuters reported. The deal is worth a reported 2 billion pounds ($3.1 billion), according to the Times. GlaxoSmithKline recently put up for sale several businesses marketing over-the-counter products.

DealsNorth AmericaUSBriefs